The problem of syphilis and gonorrhea today.

W. L. Fleming

DOI: https://doi.org/10.1080/00039896.1966.10664574

1966-09-01

Archives of Environmental Health An International Journal

Abstract:

What problem does this paper attempt to address?

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Ivan Barilar,Simone Battaglia,Emanuele Borroni,Angela Pires Brandao,Alice Brankin,Andrea Maurizio Cabibbe,Joshua Carter,Darren Chetty,Daniela Maria Cirillo,Pauline Claxton,David A. Clifton,Ted Cohen,Jorge Coronel,Derrick W. Crook,Viola Dreyer,Sarah G. Earle,Vincent Escuyer,Lucilaine Ferrazoli,Philip W. Fowler,George Fu Gao,Jennifer Gardy,Saheer Gharbia,Kelen Teixeira Ghisi,Arash Ghodousi,Ana Luíza Gibertoni Cruz,Louis Grandjean,Clara Grazian,Ramona Groenheit,Jennifer L. Guthrie,Wencong He,Harald Hoffmann,Sarah J. Hoosdally,Martin Hunt,Zamin Iqbal,Nazir Ahmed Ismail,Lisa Jarrett,Lavania Joseph,Ruwen Jou,Priti Kambli,Rukhsar Khot,Jeff Knaggs,Anastasia Koch,Donna Kohlerschmidt,Samaneh Kouchaki,Alexander S. Lachapelle,Ajit Lalvani,Simon Grandjean Lapierre,Ian F. Laurenson,Brice Letcher,Wan-Hsuan Lin,Chunfa Liu,Dongxin Liu,Kerri M. Malone,Ayan Mandal,Mikael Mansjö,Daniela Vicente Lucena Calisto Matias,Graeme Meintjes,Flávia de Freitas Mendes,Matthias Merker,Marina Mihalic,James Millard,Paolo Miotto,Nerges Mistry,David Moore,Kimberlee A. Musser,Dumisani Ngcamu,Hoang Ngoc Nhung,Stefan Niemann,Kayzad Soli Nilgiriwala,Camus Nimmo,Max O'Donnell,Nana Okozi,Rosangela Siqueira Oliveira,Shaheed Vally Omar,Nicholas Paton,Timothy E. A. Peto,Juliana Maira Watanabe Pinhata,Sara Plesnik,Zully M. Puyen,Marie Sylvianne Rabodoarivelo,Niaina Rakotosamimanana,Paola M. V. Rancoita,Priti Rathod,Esther Rhiannon Robinson,Gillian Rodger,Camilla Rodrigues,Timothy C. Rodwell,Aysha Roohi,David Santos-Lazaro,Sanchi Shah,Grace Smith,Thomas Andreas Kohl,Walter Solano,Andrea Spitaleri,Adrie J. C. Steyn,Philip Supply,Utkarsha Surve,Sabira Tahseen,Nguyen Thuy Thuong Thuong,Guy Thwaites,Katharina Todt,Alberto Trovato,Christian Utpatel,Annelies Van Rie,Srinivasan Vijay,A. Sarah Walker,Timothy M. Walker,Robin Warren,Jim Werngren,Maria Wijkander,Robert J. Wilkinson,Daniel J. Wilson,Penelope Wintringer,Yu-Xin Xiao,Yang Yang,Zhao Yanlin,Shen-Yuan Yao,Baoli Zhu

DOI: https://doi.org/10.1038/s41467-023-44325-5

IF: 16.6

2024-01-12

Nature Communications

Abstract:The World Health Organization has a goal of universal drug susceptibility testing for patients with tuberculosis. However, molecular diagnostics to date have focused largely on first-line drugs and predicting susceptibilities in a binary manner (classifying strains as either susceptible or resistant). Here, we used a multivariable linear mixed model alongside whole genome sequencing and a quantitative microtiter plate assay to relate genomic mutations to minimum inhibitory concentration (MIC) in 15,211 Mycobacterium tuberculosis clinical isolates from 23 countries across five continents. We identified 492 unique MIC-elevating variants across 13 drugs, as well as 91 mutations likely linked to hypersensitivity. Our results advance genetics-based diagnostics for tuberculosis and serve as a curated training/testing dataset for development of drug resistance prediction algorithms.

multidisciplinary sciences
HSJ people. Cast adrift.

J. Fagan

2004-02-12

Abstract:
Phenylglyoxylate decarboxylase and phenylpyruvate decarboxylase fromAcinetobacter calcoaceticus

M. Barrowman,C. A. Fewson

DOI: https://doi.org/10.1007/BF01573337

IF: 2.343

1985-07-01

Current Microbiology

Abstract:
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis

Lindsay Sonnenkalb,Joshua James Carter,Andrea Spitaleri,Zamin Iqbal,Martin Hunt,Kerri Marie Malone,Christian Utpatel,Daniela Maria Cirillo,Camilla Rodrigues,Kayzad Soli Nilgiriwala,Philip William Fowler,Matthias Merker,Stefan Niemann,Comprehensive Resistance Prediction for Tuberculosis: an International Consortium,Ivan Barilar,Simone Battaglia,Emanuele Borroni,Angela Pires Brandao,Alice Brankin,Andrea Maurizio Cabibbe,Joshua Carter,Pauline Claxton,David A Clifton,Ted Cohen,Jorge Coronel,Derrick W Crook,Viola Dreyer,Sarah G Earle,Vincent Escuyer,Lucilaine Ferrazoli,Philip W Fowler,George Fu Gao,Jennifer Gardy,Saheer Gharbia,Kelen Teixeira Ghisi,Arash Ghodousi,Ana Luíza Gibertoni Cruz,Louis Grandjean,Clara Grazian,Ramona Groenheit,Jennifer L Guthrie,Wencong He,Harald Hoffmann,Sarah J Hoosdally,Nazir Ahmed Ismail,Lisa Jarrett,Lavania Joseph,Ruwen Jou,Priti Kambli,Rukhsar Khot,Jeff Knaggs,Anastasia Koch,Donna Kohlerschmidt,Samaneh Kouchaki,Alexander S Lachapelle,Ajit Lalvani,Simon Grandjean Lapierre,Ian F Laurenson,Brice Letcher,Wan-Hsuan Lin,Chunfa Liu,Dongxin Liu,Kerri M Malone,Ayan Mandal,Mikael Mansjö,Daniela Matias,Graeme Meintjes,Flávia de Freitas Mendes,Marina Mihalic,James Millard,Paolo Miotto,Nerges Mistry,David Moore,Kimberlee A Musser,Dumisani Ngcamu,Ngoc Nhung Hoang,Camus Nimmo,Nana Okozi,Rosangela Siqueira Oliveira,Shaheed Vally Omar,Nicholas Paton,Timothy Ea Peto,Juliana Maira Watanabe Pinhata,Sara Plesnik,Zully M Puyen,Marie Sylvianne Rabodoarivelo,Niaina Rakotosamimanana,Paola Mv Rancoita,Priti Rathod,Gillian Rodger,Timothy C Rodwell,Eaysha Roohi,David Santos-Lazaro,Sanchi Shah,Thomas Andreas Kohl,Grace Smith,Walter Solano,Philip Supply,Utkarsha Surve,Sabira Tahseen,Nguyen Thuy Thuong Thuong,Guy Thwaites,Katharina Todt,Alberto Trovato,Annelies Van Rie,Srinivasan Vijay,Timothy M Walker,Sarah A Walker,Robin Warren,Jim Werngren,Maria Wijkander,Robert J Wilkinson,Daniel J Wilson,Penelope Wintringer,Xin Xiao Yu,Yang Yang,Yanlin Zhao,Shen-Yuan Yao,Baoli Zhu

DOI: https://doi.org/10.1016/S2666-5247(23)00002-2

Abstract:Background: Bedaquiline is a core drug for the treatment of multidrug-resistant tuberculosis; however, the understanding of resistance mechanisms is poor, which is hampering rapid molecular diagnostics. Some bedaquiline-resistant mutants are also cross-resistant to clofazimine. To decipher bedaquiline and clofazimine resistance determinants, we combined experimental evolution, protein modelling, genome sequencing, and phenotypic data. Methods: For this in-vitro and in-silico data analysis, we used a novel in-vitro evolutionary model using subinhibitory drug concentrations to select bedaquiline-resistant and clofazimine-resistant mutants. We determined bedaquiline and clofazimine minimum inhibitory concentrations and did Illumina and PacBio sequencing to characterise selected mutants and establish a mutation catalogue. This catalogue also includes phenotypic and genotypic data of a global collection of more than 14 000 clinical Mycobacterium tuberculosis complex isolates, and publicly available data. We investigated variants implicated in bedaquiline resistance by protein modelling and dynamic simulations. Findings: We discerned 265 genomic variants implicated in bedaquiline resistance, with 250 (94%) variants affecting the transcriptional repressor (Rv0678) of the MmpS5-MmpL5 efflux system. We identified 40 new variants in vitro, and a new bedaquiline resistance mechanism caused by a large-scale genomic rearrangement. Additionally, we identified in vitro 15 (7%) of 208 mutations found in clinical bedaquiline-resistant isolates. From our in-vitro work, we detected 14 (16%) of 88 mutations so far identified as being associated with clofazimine resistance and also seen in clinically resistant strains, and catalogued 35 new mutations. Structural modelling of Rv0678 showed four major mechanisms of bedaquiline resistance: impaired DNA binding, reduction in protein stability, disruption of protein dimerisation, and alteration in affinity for its fatty acid ligand. Interpretation: Our findings advance the understanding of drug resistance mechanisms in M tuberculosis complex strains. We have established an extended mutation catalogue, comprising variants implicated in resistance and susceptibility to bedaquiline and clofazimine. Our data emphasise that genotypic testing can delineate clinical isolates with borderline phenotypes, which is essential for the design of effective treatments. Funding: Leibniz ScienceCampus Evolutionary Medicine of the Lung, Deutsche Forschungsgemeinschaft, Research Training Group 2501 TransEvo, Rhodes Trust, Stanford University Medical Scientist Training Program, National Institute for Health and Care Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Bill & Melinda Gates Foundation, Wellcome Trust, and Marie Skłodowska-Curie Actions.
Universal Lineage-Independent Markers of Multidrug Resistance in Mycobacterium tuberculosis

Hleliwe Hlanze,Awelani Mutshembele,Oleg N. Reva

DOI: https://doi.org/10.3390/microorganisms12071340

IF: 4.5

2024-06-30

Microorganisms

Abstract:(1) Background: This study was aimed to identify universal genetic markers of multidrug resistance (MDR) in Mycobacterium tuberculosis (Mtb) and establish statistical associations among identified mutations to enhance understanding of MDR in Mtb and inform diagnostic and treatment development. (2) Methods: GWAS analysis and the statistical evaluation of identified polymorphic sites within protein-coding genes of Mtb were performed. Statistical associations between specific mutations and antibiotic resistance were established using attributable risk statistics. (3) Results: Sixty-four polymorphic sites were identified as universal markers of drug resistance, with forty-seven in PE/PPE regions and seventeen in functional genes. Mutations in genes such as cyp123, fadE36, gidB, and ethA showed significant associations with resistance to various antibiotics. Notably, mutations in cyp123 at codon position 279 were linked to resistance to ten antibiotics. The study highlighted the role of PE/PPE and PE_PGRS genes in Mtb’s evolution towards a ‘mutator phenotype’. The pathways of acquisition of mutations forming the epistatic landscape of MDR were discussed. (4) Conclusions: This research identifies marker mutations across the Mtb genome associated with MDR. The findings provide new insights into the molecular basis of MDR acquisition in Mtb, aiding in the development of more effective diagnostics and treatments targeting these mutations to combat MDR tuberculosis.

microbiology
[Saliva and dental caries: diagnostic tests in practical dentistry].

D. Rostoka,Iu Kroĭcha,V. Kuznetsova,D. Brazma,A. Reinis

Abstract:New qualitative methods of diagnosis are used now in dental practice. Very popular are saliva diagnostic tests. They are fast and convenient for use. By the saliva one can make diagnosis on the caries activity because of wrong diet (Lactobacillus bacteria in saliva), elevated level of cariogenic microorganisms in saliva (Streptococcus mutans level in saliva) and saliva pH. It is possible to detect the level of Streptococcus mutans and Lactobacillus in saliva using selective diagnostic medium for the bacterial culture.
Leveraging large-scale Mycobacterium tuberculosis whole genome sequence data to characterise drug-resistant mutations using machine learning and statistical approaches

Siddharth Sanjay Pruthi,Nina Billows,Joseph Thorpe,Susana Campino,Jody E. Phelan,Fady Mohareb,Taane G. Clark

DOI: https://doi.org/10.1038/s41598-024-77947-w

IF: 4.6

2024-11-09

Scientific Reports

Abstract:Tuberculosis disease (TB), caused by Mycobacterium tuberculosis ( Mtb ), is a major global public health problem, resulting in > 1 million deaths each year. Drug resistance (DR), including the multi-drug form (MDR-TB), is challenging control of the disease. Whilst many DR mutations in the Mtb genome are known, analysis of large datasets generated using whole genome sequencing (WGS) platforms can reveal new variants through the assessment of genotype-phenotype associations. Here, we apply tree-based ensemble methods to a dataset comprised of 35,777 Mtb WGS and phenotypic drug-susceptibility test data across first- and second-line drugs. We compare model performance across models trained using mutations in drug-specific regions and genome-wide variants, and find high predictive ability for both first-line (area under ROC curve (AUC); range 88.3–96.5) and second-line (AUC range 84.1–95.4) drugs. To aggregate information from low-frequency variants, we pool mutations by functional impact and observe large improvements in predictive accuracy (e.g., sensitivity: pyrazinamide + 25%; ethionamide + 10%). We further characterise loss-of-function mutations observed in resistant phenotypes, uncovering putative markers of resistance (e.g., ndh 293dupG, Rv3861 78delC). Finally, we profile the distribution of known DR-associated single nucleotide polymorphisms across discretised minimum inhibitory concentration (MIC) data generated from phenotypic testing ( n = 12,066), and identify mutations associated with highly resistant phenotypes (e.g., inhA − 779G > T and 62T > C). Overall, our work demonstrates that applying machine learning to large-scale WGS data is useful for providing insights into predicting Mtb binary drug resistance and MIC phenotypes, thereby potentially assisting diagnosis and treatment decision-making for infection control.

multidisciplinary sciences
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan

Abdul Jabbar,Jody E. Phelan,Paola Florez de Sessions,Taj Ali Khan,Hazir Rahman,Sadiq Noor Khan,Daire M. Cantillon,Leticia Muraro Wildner,Sajid Ali,Susana Campino,Simon J. Waddell,Taane G. Clark

DOI: https://doi.org/10.1038/s41598-019-51562-6

IF: 4.6

2019-10-18

Scientific Reports

Abstract:Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis bacteria, is a leading infectious cause of mortality worldwide, including in Pakistan. Drug resistant M. tuberculosis is an emerging threat for TB control, making it important to detect the underlying genetic mutations, and thereby inform treatment decision making and prevent transmission. Whole genome sequencing has emerged as the new diagnostic to reliably predict drug resistance within a clinically relevant time frame, and its deployment will have the greatest impact on TB control in highly endemic regions. To evaluate the mutations leading to drug resistance and to assess for evidence of the transmission of resistant strains, 81 M. tuberculosis samples from Khyber Pakhtunkhwa province (North West Pakistan) were subjected to whole genome sequencing and standard drug susceptibility testing for eleven anti-TB drugs. We found the majority of M. tuberculosis isolates were the CAS/Delhi strain-type (lineage 3; n = 57; 70.4%) and multi-drug resistant (MDR; n = 62; 76.5%). The most frequent resistance mutations were observed in the katG and rpoB genes, conferring resistance to isoniazid and rifampicin respectively. Mutations were also observed in genes conferring resistance to other first and second-line drugs, including in pncA (pyrazinamide), embB (ethambutol), gyrA (fluoroquinolones), rrs (aminoglycosides), rpsL, rrs and giB (streptomycin) loci. Whilst the majority of mutations have been reported in global datasets, we describe unreported putative resistance markers in katG , ethA (ethionamide), gyrA and gyrB (fluoroquinolones), and pncA . Analysis of the mutations revealed that acquisition of rifampicin resistance often preceded isoniazid in our isolates. We also observed a high proportion (17.6%) of pre-MDR isolates with fluoroquinolone resistance markers, potentially due to unregulated anti-TB drug use. Our isolates were compared to previously sequenced strains from Pakistan in a combined phylogenetic tree analysis. The presence of lineage 2 was only observed in our isolates. Using a cut-off of less than ten genome-wide mutation differences between isolates, a transmission analysis revealed 18 M. tuberculosis isolates clustering within eight networks, thereby providing evidence of drug-resistant TB transmission in the Khyber Pakhtunkhwa province. Overall, we have demonstrated that drug-resistant TB isolates are circulating and transmitted in North West Pakistan. Further, we have shown the usefulness of whole genome sequencing as a diagnostic tool for characterizing M. tuberculosis isolates, which will assist future epidemiological studies and disease control activities in Pakistan.

multidisciplinary sciences
Genetic Characterization and Population Structure of Drug-Resistant Mycobacterium tuberculosis Isolated from Brazilian Patients Using Whole-Genome Sequencing

Leonardo Souza Esteves,Lia Lima Gomes,Daniela Brites,Fátima Cristina Onofre Fandinho,Marcela Bhering,Márcia Aparecida da Silva Pereira,Emilyn Costa Conceição,Richard Salvato,Bianca Porphirio da Costa,Reginalda Ferreira de Melo Medeiros,Paulo Cesar de Souza Caldas,Paulo Redner,Margareth Pretti Dalcolmo,Vegard Eldholm,Sebastien Gagneux,Maria Lucia Rossetti,Afrânio Lineu Kritski,Philip Noel Suffys

DOI: https://doi.org/10.3390/antibiotics13060496

2024-05-29

Antibiotics

Abstract:The present study aimed to determine the genetic diversity of isolates of Mycobacterium tuberculosis (Mtb) from presumed drug-resistant tuberculosis patients from several states of Brazil. The isolates had been submitted to conventional drug susceptibility testing for first- and second-line drugs. Multidrug-resistant (MDR-TB) (54.8%) was the most frequent phenotypic resistance profile, in addition to an important high frequency of pre-extensive resistance (p-XDR-TB) (9.2%). Using whole-genome sequencing (WGS), we characterized 298 Mtb isolates from Brazil. Besides the analysis of genotype distribution and possible correlations between molecular and clinical data, we determined the performance of an in-house WGS pipeline with other online pipelines for Mtb lineages and drug resistance profile definitions. Sub-lineage 4.3 (52%) was the most frequent genotype, and the genomic approach revealed a p-XDR-TB level of 22.5%. We detected twenty novel mutations in three resistance genes, and six of these were observed in eight phenotypically resistant isolates. A cluster analysis of 170 isolates showed that 43.5% of the TB patients belonged to 24 genomic clusters, suggesting considerable ongoing transmission of DR-TB, including two interstate transmissions. The in-house WGS pipeline showed the best overall performance in drug resistance prediction, presenting the best accuracy values for five of the nine drugs tested. Significant associations were observed between suffering from fatal disease and genotypic p-XDR-TB (p = 0.03) and either phenotypic (p = 0.006) or genotypic (p = 0.0007) ethambutol resistance. The use of WGS analysis improved our understanding of the population structure of MTBC in Brazil and the genetic and clinical data correlations and demonstrated its utility for surveillance efforts regarding the spread of DR-TB, hopefully helping to avoid the emergence of even more resistant strains and to reduce TB incidence and mortality rates.

pharmacology & pharmacy,infectious diseases
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis

Timothy M Walker,Paolo Miotto,Claudio U Köser,Philip W Fowler,Jeff Knaggs,Zamin Iqbal,Martin Hunt,Leonid Chindelevitch,Maha R Farhat,Daniela Maria Cirillo,Iñaki Comas,James Posey,Shaheed V Omar,Timothy EA Peto,Anita Suresh,Swapna Uplekar,Sacha Laurent,Rebecca E Colman,Carl-Michael Nathanson,Matteo Zignol,Ann Sarah Walker,Derrick W Crook,Nazir Ismail,Timothy C Rodwell,the SeqTreat Consortium CRyPTIC Consortium,A Sarah Walker,Adrie J C Steyn,Ajit Lalvani,Alain Baulard,Alan Christoffels,Alberto Mendoza-Ticona,Alberto Trovato,Alena Skrahina,Alexander S Lachapelle,Alice Brankin,Amy Piatek,Ana Gibertoni Cruz,Anastasia Koch,Andrea Maurizio Cabibbe,Andrea Spitaleri,Angela P Brandao,Angkana Chaiprasert,Anita Suresh,Anna Barbova,Annelies Van Rie,Arash Ghodousi,Arnold Bainomugisa,Ayan Mandal,Aysha Roohi,Babak Javid,Baoli Zhu,Brice Letcher,Camilla Rodrigues,Camus Nimmo,Carl-Michael NATHANSON,Carla Duncan,Christopher Coulter,Christian Utpatel,Chunfa Liu,Clara Grazian,Clare Kong,Claudio U Köser,Daniel J Wilson,Daniela Maria Cirillo,Daniela Matias,Danielle Jorgensen,Danila Zimenkov,Darren Chetty,David AJ Moore,David A Clifton,Derrick W Crook,Dick van Soolingen,Dongxin Liu,Donna Kohlerschmidt,Draurio Barreira,Dumisani Ngcamu,Elias David Santos Lazaro,Ellis Kelly,Emanuele Borroni,Emma Roycroft,Emmanuel Andre,Erik C Böttger,Esther Robinson,Fabrizio Menardo,Flavia F Mendes,Frances B Jamieson,Francesc Coll,George Fu Gao,George W Kasule,Gian Maria Rossolini,Gillian Rodger,E Grace Smith,Graeme Meintjes,Guy Thwaites,Harald Hoffmann,Heidi Albert,Helen Cox,Ian F Laurenson,Iñaki Comas,Irena Arandjelovic,Ivan Barilar,Jaime Robledo,James Millard,James Johnston,Jamie Posey,Jason R Andrews,Jeff Knaggs,Jennifer Gardy,Jennifer Guthrie,Jill Taylor,Jim Werngren,John Metcalfe,Jorge Coronel,Joseph Shea,Joshua Carter,Juliana MW Pinhata,Julianne V Kus,Katharina Todt,Kathryn Holt,Kayzad S Nilgiriwala,Kelen T Ghisi,Kerri M Malone,Kiatichai Faksri,Kimberlee A Musser,Lavania Joseph,Leen Rigouts,Leonid Chindelevitch,Lisa Jarrett,Louis Grandjean,Lucilaine Ferrazoli,Mabel Rodrigues,Maha Farhat,Marco Schito,Margaret M Fitzgibbon,Marguerite Massinga Loembé,Maria Wijkander,Marie Ballif,Marie-Sylvianne Rabodoarivelo,Marina Mihalic,Mark WILCOX,Martin Hunt,Matteo ZIGNOL,Matthias Merker,Matthias Egger,Max O'Donnell,Maxine Caws,Mei-Hua Wu,Michael G Whitfield,Michael Inouye,Mikael Mansjö,Minh Ha Dang Thi,Moses Joloba,SM Mostofa Kamal,Nana Okozi,Nazir ISMAIL,Nerges Mistry,Nhung N Hoang,Niaina Rakotosamimanana,Nicholas I Paton,Paola M V Rancoita,Paolo Miotto,Pascal Lapierre,Patricia J Hall,Patrick Tang,Pauline Claxton,Penelope Wintringer,Peter M Keller,Phan Vuong Khac Thai,Philip W Fowler,Philip Supply,Prapaporn Srilohasin,Prapat Suriyaphol,Priti Rathod,Priti Kambli,Ramona Groenheit,Rebecca E Colman,Rick Twee-Hee Ong,Robin M Warren,Robert J Wilkinson,Roland Diel,Rosangela S Oliveira,Rukhsar Khot,Ruwen Jou,Sabira Tahseen,Sacha Laurent,Saheer Gharbia,Samaneh Kouchaki,Sanchi Shah,Sara Plesnik,Sarah G Earle,Sarah Dunstan,Sarah J Hoosdally,Satoshi Mitarai,Sebastien Gagneux,Shaheed V Omar,Shen-Yuan Yao,Simon Grandjean Lapierre,Simone Battaglia,Stefan Niemann,Sushil Pandey,Swapna Uplekar,Tanya A Halse,Ted Cohen,Teresa Cortes,Therdsak Prammananan,Thomas A Kohl,Nguyen T T Thuong,Tik Ying Teo,Timothy E A Peto,Timothy C Rodwell,Timothy William,Timothy M Walker,Thomas R Rogers,Utkarsha Surve,Vanessa Mathys,Victoria Furió,Victoria Cook,Srinivasan Vijay,Vincent Escuyer,Viola Dreyer,Vitali Sintchenko,Vonthanak Saphonn,Walter Solano,Wan-Hsuan Lin,Wayne van Gemert,Wencong He,Yang Yang,Yanlin Zhao,Youwen Qin,Yu-Xin Xiao,Zahra Hasan,Zamin Iqbal,Zully M Puyen

DOI: https://doi.org/10.1016/s2666-5247(21)00301-3

IF: 86.208

2022-04-01

The Lancet Microbe

Abstract:Background: Molecular diagnostics are considered the most promising route to achieving rapid, universal drug susceptibility testing for <i>Mycobacterium tuberculosis</i>complex (MTBC). We aimed to generate a WHO endorsed catalogue of mutations to serve as a global standard for interpreting molecular information for drug resistance prediction.Methods: A candidate gene approach was used to identify mutations as associated with resistance, or consistent with susceptibility, for 13 WHO endorsed anti-tuberculosis drugs. 38,215 MTBC isolates with paired whole-genome sequencing and phenotypic drug susceptibility testing data were amassed from 45 countries. For each mutation, a contingency table of binary phenotypes and presence or absence of the mutation computed positive predictive value, and Fisher's exact tests generated odds ratios and Benjamini-Hochberg corrected p-values. Mutations were graded as Associated with Resistance if present in at least 5 isolates, if the odds ratio was >1 with a statistically significant corrected p-value, and if the lower bound of the 95% confidence interval on the positive predictive value for phenotypic resistance was >25%. A series of expert rules were applied for final confidence grading of each mutation.Findings: 15,667 associations were computed for 13,211 unique mutations linked to one or more drugs. 1,149/15,667 (7·3%) mutations were classified as associated with phenotypic resistance and 107/15,667 (0·7%) were deemed consistent with susceptibility. For rifampicin, isoniazid, ethambutol, fluoroquinolones, and streptomycin, the mutations' pooled sensitivity was >80%. Specificity was over 95% for all drugs except ethionamide (91·4%), moxifloxacin (91·6%) and ethambutol (93·3%). Only two resistance mutations were classified for bedaquiline, delamanid, clofazimine, and linezolid as prevalence of phenotypic resistance was low for these drugs.Interpretation: This first WHO endorsed catalogue of molecular targets for MTBC drug susceptibility testing provides a global standard for resistance interpretation. Its existence should encourage the implementation of molecular diagnostics by National Tuberculosis Programmes.Funding: UNITAID, Wellcome, MRC, BMGF.

medicine, general & internal
Mutations in Dnaa and a Cryptic Interaction Site Increase Drug Resistance in Mycobacterium Tuberculosis.

Nathan D. Hicks,Samantha R. Giffen,Peter H. Culviner,Michael C. Chao,Charles L. Dulberger,Qingyun Liu,Sydney Stanley,Jessica Brown,Jaimie Sixsmith,Ian D. Wolf,Sarah M. Fortune

DOI: https://doi.org/10.1371/journal.ppat.1009063

IF: 7.464

2020-01-01

PLoS Pathogens

Abstract:Genomic dissection of antibiotic resistance in bacterial pathogens has largely focused on genetic changes conferring growth above a single critical concentration of drug. However, reduced susceptibility to antibiotics-even below this breakpoint-is associated with poor treatment outcomes in the clinic, including in tuberculosis. Clinical strains of Mycobacterium tuberculosis exhibit extensive quantitative variation in antibiotic susceptibility but the genetic basis behind this spectrum of drug susceptibility remains ill-defined. Through a genome wide association study, we show that non-synonymous mutations in dnaA, which encodes an essential and highly conserved regulator of DNA replication, are associated with drug resistance in clinical M. tuberculosis strains. We demonstrate that these dnaA mutations specifically enhance M. tuberculosis survival during isoniazid treatment via reduced expression of katG, the activator of isoniazid. To identify DnaA interactors relevant to this phenotype, we perform the first genome-wide biochemical mapping of DnaA binding sites in mycobacteria which reveals a DnaA interaction site that is the target of recurrent mutation in clinical strains. Reconstructing clinically prevalent mutations in this DnaA interaction site reproduces the phenotypes of dnaA mutants, suggesting that clinical strains of M. tuberculosis have evolved mutations in a previously uncharacterized DnaA pathway that quantitatively increases resistance to the key first-line antibiotic isoniazid. Discovering genetic mechanisms that reduce drug susceptibility and support the evolution of high-level drug resistance will guide development of biomarkers capable of prospectively identifying patients at risk of treatment failure in the clinic.
Whole-genome sequencing-based genetic diversity, transmission dynamics, and drug-resistant mutations in Mycobacterium tuberculosis isolated from extrapulmonary tuberculosis patients in western Ethiopia

Basha Chekesa,Harinder Singh,Norberto Gonzalez-Juarbe,Sanjay Vashee,Rosana Wiscovitch-Russo,Christopher L Dupont,Musse Girma,Oudessa Kerro,Balako Gumi,Gobena Ameni

DOI: https://doi.org/10.3389/fpubh.2024.1399731

2024-08-09

Abstract:Background: Extrapulmonary tuberculosis (EPTB) refers to a form of Tuberculosis (TB) where the infection occurs outside the lungs. Despite EPTB being a devastating disease of public health concern, it is frequently overlooked as a public health problem. This study aimed to investigate genetic diversity, identify drug-resistance mutations, and trace ongoing transmission chains. Methods: A cross-sectional study was undertaken on individuals with EPTB in western Ethiopia. In this study, whole-genome sequencing (WGS) was employed to analyze Mycobacterium tuberculosis (MTB) samples obtained from EPTB patients. Out of the 96 genomes initially sequenced, 89 met the required quality standards for genetic diversity, and drug-resistant mutations analysis. The data were processed using robust bioinformatics tools. Results: Our analysis reveals that the majority (87.64%) of the isolates can be attributed to Lineage-4 (L4), with L4.6.3 and L4.2.2.2 emerging as the predominant sub-lineages, constituting 34.62% and 26.92%, respectively. The overall clustering rate and recent transmission index (RTI) were 30 and 17.24%, respectively. Notably, 7.87% of the isolates demonstrated resistance to at least one anti-TB drug, although multi-drug resistance (MDR) was observed in only 1.12% of the isolates. Conclusions: The genetic diversity of MTBC strains in western Ethiopia was found to have low inter-lineage diversity, with L4 predominating and exhibiting high intra-lineage diversity. The notably high clustering rate in the region implies a pressing need for enhanced TB infection control measures to effectively disrupt the transmission chain. It's noteworthy that 68.75% of resistance-conferring mutations went undetected by both GeneXpert MTB/RIF and the line probe assay (LPA) in western Ethiopia. The identification of resistance mutations undetected by both GeneXpert and LPA, along with the detection of mixed infections through WGS, emphasizes the value of adopting WGS as a high-resolution approach for TB diagnosis and molecular epidemiological surveillance.
Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis

S. Morris,G. H. Bai,P. Suffys,L. Portillo-Gomez,M. Fairchok,D. Rouse

DOI: https://doi.org/10.1093/infdis/171.4.954

1995-04-01

Abstract:The molecular mechanisms of resistance to streptomycin, rifampin, and isoniazid in 53 Mycobacterium tuberculosis clinical isolates were examined. Twenty-five of 44 streptomycin-resistant strains had mutations in the rpsL gene and 5 of these had rrs gene perturbations. The region of the rpoB gene that is associated with resistance to rifampin was altered in 28 of 29 rifampin-resistant strains. Mutations in known genetic markers of isoniazid resistance were detected in 25 of 42 isoniazid-resistant isolates: 20 strains had katG gene alterations and 5 had perturbations in the inhA operon. Of the 20 multiply resistant strains with reduced sensitivity to streptomycin, rifampin, and isoniazid, 11 had mutations in genetic markers associated with resistance to each of these three drugs. These studies suggest that the primary mechanism of multiple drug resistance in tuberculosis is the accumulation of mutations in individual drug target genes.

immunology,infectious diseases,microbiology
Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in Pakistan

Gary Napier,Anwar Sheed Khan,Abdul Jabbar,Muhammad Tahir Khan,Sajid Ali,Muhammad Qasim,Noor Mohammad,Rumina Hasan,Zahra Hasan,Susana Campino,Sajjad Ahmad,Baharullah Khattak,Simon J. Waddell,Taj Ali Khan,Jody E. Phelan,Taane G. Clark

DOI: https://doi.org/10.1038/s41598-022-11795-4

IF: 4.6

2022-05-11

Scientific Reports

Abstract:Tuberculosis, caused by Mycobacterium tuberculosis, is a high-burden disease in Pakistan, with multi-drug (MDR) and extensive-drug (XDR) resistance, complicating infection control. Whole genome sequencing (WGS) of M. tuberculosis is being used to infer lineages (strain-types), drug resistance mutations, and transmission patterns—all informing infection control and clinical decision making. Here we analyse WGS data on 535 M. tuberculosis isolates sourced across Pakistan between years 2003 and 2020, to understand the circulating strain-types and mutations related to 12 anti-TB drugs, as well as identify transmission clusters. Most isolates belonged to lineage 3 (n = 397; 74.2%) strain-types, and were MDR (n = 328; 61.3%) and (pre-)XDR (n = 113; 21.1%). By inferring close genomic relatedness between isolates (< 10-SNPs difference), there was evidence of M. tuberculosis transmission, with 55 clusters formed consisting of a total of 169 isolates. Three clusters consist of M. tuberculosis that are similar to isolates found outside of Pakistan. A genome-wide association analysis comparing 'transmitted' and 'non-transmitted' isolate groups, revealed the nusG gene as most significantly associated with a potential transmissible phenotype (P = 5.8 × 10 –10 ). Overall, our study provides important insights into M. tuberculosis genetic diversity and transmission in Pakistan, including providing information on circulating drug resistance mutations for monitoring activities and clinical decision making.

multidisciplinary sciences
Drug Resistance-Related Mutations in Multidrug-Resistant Mycobacterium Tuberculosis Isolates from Diverse Geographical Regions.

Senia Rosales-Klintz,Pontus Jureen,Aksana Zalutskayae,Alena Skrahina,Biao Xu,Yi Hu,Lelany Pineda-Garcia,Muayad Aghali Merza,Ionela Muntean,Freddie Bwanga,Moses Joloba,Sven E. Hoffner

DOI: https://doi.org/10.1016/j.ijmyco.2012.08.001

2012-01-01

International Journal of Mycobacteriology

Abstract:Background: Drug resistance in Mycobacterium tuberculosis is associated with chromosomal mutations in selected genes. These mutations can be screened for an early warning system for drug-resistant tuberculosis. The prevalence of individual mutations differs geographically, which must be considered in developing globally applicable screening tests. Methods: In order to analyse the geographical distribution and frequency of mutations conferring resistance to rifampicin, isoniazid and fluoroquinolones, the researchers investigated the presence of mutations in the rpoB gene, the katG gene, the mabA-inhA promoter region and the gyrA gene in clinical isolates of multidrug-resistant tuberculosis (MDR-TB) from Belarus, China, Iran/Iraq, Honduras, Romania and Uganda. For each study site, the researchers described the distribution of specific mutations in 20 clinical MDR-isolates. Results: The distribution of resistance-related mutations varied significantly between the study sites. Settings with a high incidence of MDR-TB, such as Belarus, showed a narrower spectrum of mutations related to rifampicin and isoniazid resistance and also a higher prevalence of fluoroquinolone resistance than study sites with a lower MDR-TB prevalence. Conclusion: This study confirms that there are significant geographical differences in the distribution of resistance-related mutations and suggests that an increased understanding of such differences in the specific distribution of resistance conferring mutations is crucial for development of new, generally applicable, molecular tools for rapid diagnosis of drug-resistant TB. The fact that a narrower distribution of mutations in high MDR-TB prevalence settings was seen suggests that much of the problems in these settings can be a result of an ongoing transmission of certain MDR-TB strains.
Overexpression of COX-2 but not indoleamine 2,3-dioxygenase-1 enhances the immunosuppressive ability of human umbilical cord-derived mesenchymal stem cells.

Dong Li,Yan Han,Y. Zhuang,Jinqiu Fu,Huang Liu,Qing Shi,X. Ju

DOI: https://doi.org/10.3892/ijmm.2015.2137

IF: 5.314

2015-05-01

International Journal of Molecular Medicine

Abstract:Owing to their immunosuppressive properties mesenchymal stem cells (MSCs) are widely applicable in the treatment of autoimmune disease. The aim of this study was to investigate whether the indoleamine 2,3-dioxygenase-1 (IDO-1) and cyclooxygenase-2 (COX-2) genes enhanced the immunosuppressive functional ability of MSCs following stable transfection. To strengthen the immunomodulatory ability of MSCs, IDO-1 and COX-2 were overexpressed in umbilical cord progenitor cell-derived MSCs using recombinant plasmids and electroporation. RT-qPCR analysis and western blotting confirmed the expression of IDO-1 and COX-2 in transfected MSCs. Further functional assays in co-culture experiments, including lymphocyte proliferation and cyto-toxicity assays showed that COX-2-transfected MSCs possessed more potent immunomodulatory cells than the untreated MSCs, or MSCs transfected with IDO-1. Additionally, synthesis of interferon-γ and tumor necrosis factor-α (TNF-α) was significantly inhibited in lymphocytes co-cultured with COX-2-transfected MSCs, which was consistent with changes in immune-related genes in MSCs. An enhanced expression of IDO-1, COX-2, heme-oxygenase-1, inducible nitric-oxide synthase, TNF-α-stimulated gene/protein-6, transforming growth factor-β (TGF-β), human leukocyte antigen molecule 5 (HLA-G5) and interleukin-10 (IL-10) was identified following COX-2 transfection. We showed that the overexpression of COX-2 enhanced the immunosuppressive function of MSCs. COX-2-modified MSCs more potently inhibited the activation and proliferation of peripheral blood mononuclear cells.
Whole genome sequencing identifies bacterial factors affecting transmission of multidrug-resistant tuberculosis in a high-prevalence setting

Avika Dixit,Luca Freschi,Roger Vargas,Roger Calderon,James Sacchettini,Francis Drobniewski,Jerome T Galea,Carmen Contreras,Rosa Yataco,Zibiao Zhang,Leonid Lecca,Sergios-Orestis Kolokotronis,Barun Mathema,Maha R Farhat

DOI: https://doi.org/10.1038/s41598-019-41967-8

2019-04-03

Abstract:Whole genome sequencing (WGS) can elucidate Mycobacterium tuberculosis (Mtb) transmission patterns but more data is needed to guide its use in high-burden settings. In a household-based TB transmissibility study in Peru, we identified a large MIRU-VNTR Mtb cluster (148 isolates) with a range of resistance phenotypes, and studied host and bacterial factors contributing to its spread. WGS was performed on 61 of the 148 isolates. We compared transmission link inference using epidemiological or genomic data and estimated the dates of emergence of the cluster and antimicrobial drug resistance (DR) acquisition events by generating a time-calibrated phylogeny. Using a set of 12,032 public Mtb genomes, we determined bacterial factors characterizing this cluster and under positive selection in other Mtb lineages. Four of the 61 isolates were distantly related and the remaining 57 isolates diverged ca. 1968 (95%HPD: 1945-1985). Isoniazid resistance arose once and rifampin resistance emerged subsequently at least three times. Emergence of other DR types occurred as recently as within the last year of sampling. We identified five cluster-defining SNPs potentially contributing to transmissibility. In conclusion, clusters (as defined by MIRU-VNTR typing) may be circulating for decades in a high-burden setting. WGS allows for an enhanced understanding of transmission, drug resistance, and bacterial fitness factors.
Machine Learning Predicts Accurately Mycobacterium tuberculosis Drug Resistance From Whole Genome Sequencing Data

Wouter Deelder,Sofia Christakoudi,Jody Phelan,Ernest Diez Benavente,Susana Campino,Ruth McNerney,Luigi Palla,Taane G. Clark

DOI: https://doi.org/10.3389/fgene.2019.00922

IF: 3.7

2019-09-26

Frontiers in Genetics

Abstract:Background: Tuberculosis disease, caused by Mycobacterium tuberculosis, is a major public health problem. The emergence of M. tuberculosis strains resistant to existing treatments threatens to derail control efforts. Resistance is mainly conferred by mutations in genes coding for drug targets or converting enzymes, but our knowledge of these mutations is incomplete. Whole genome sequencing (WGS) is an increasingly common approach to rapidly characterize isolates and identify mutations predicting antimicrobial resistance and thereby providing a diagnostic tool to assist clinical decision making.Methods: We applied machine learning approaches to 16,688 M. tuberculosis isolates that have undergone WGS and laboratory drug-susceptibility testing (DST) across 14 antituberculosis drugs, with 22.5% of samples being multidrug resistant and 2.1% being extensively drug resistant. We used non-parametric classification-tree and gradient-boosted-tree models to predict drug resistance and uncover any associated novel putative mutations. We fitted separate models for each drug, with and without "co-occurrent resistance" markers known to be causing resistance to drugs other than the one of interest. Predictive performance was measured using sensitivity, specificity, and the area under the receiver operating characteristic curve, assuming DST results as the gold standard.Results: The predictive performance was highest for resistance to first-line drugs, amikacin, kanamycin, ciprofloxacin, moxifloxacin, and multidrug-resistant tuberculosis (area under the receiver operating characteristic curve above 96%), and lowest for third-line drugs such as D-cycloserine and Para-aminosalisylic acid (area under the curve below 85%). The inclusion of co-occurrent resistance markers led to improved performance for some drugs and superior results when compared to similar models in other large-scale studies, which had smaller sample sizes. Overall, the gradient-boosted-tree models performed better than the classification-tree models. The mutation-rank analysis detected no new single nucleotide polymorphisms linked to drug resistance. Discordance between DST and genotypically inferred resistance may be explained by DST errors, novel rare mutations, hetero-resistance, and nongenomic drivers such as efflux-pump upregulation.Conclusion: Our work demonstrates the utility of machine learning as a flexible approach to drug resistance prediction that is able to accommodate a much larger number of predictors and to summarize their predictive ability, thus assisting clinical decision making and single nucleotide polymorphism detection in an era of increasing WGS data generation.

genetics & heredity
Whole genome sequencing analysis of Mycobacterium tuberculosis reveals circulating strain types and drug-resistance mutations in the Philippines

Linfeng Wang,Dodge R. Lim,Jody E. Phelan,Lorenzo T. Reyes,Alma G. Palparan,Maria Guileane C. Sanchez,Louella Abigail A. Asuncion,Ma. Angelica A. Tujan,Inez Andrea P. Medado,Chona Mae A. Daga,Jo-Hannah S. Llames,Satoshi Mitarai,Yoshiro Murase,Yuta Morishige,Concepcion F. Ang,John Carlo M. Malabad,Jaime C. Montoya,Julius C. Hafalla,Susana Campino,Martin L. Hibberd,Cecilia G. Ama,Ramon P. Basilio,Eva Maria Cutiongoco-De La Paz,Taane G. Clark

DOI: https://doi.org/10.1038/s41598-024-70471-x

IF: 4.6

2024-08-26

Scientific Reports

Abstract:The Philippines is a high-incidence country for tuberculosis, with the increasing prevalence of multi- (MDR-TB) and extensively-drug (XDR-TB) resistant Mycobacterium tuberculosis strains posing difficulties to disease control. Understanding the genetic diversity of circulating strains can provide insights into underlying drug resistance mutations and transmission dynamics, thereby assisting the design of diagnostic tools, including those using next generation sequencing (NGS) platforms. By analysing genome sequencing data of 732 isolates from Philippines drug-resistance survey collections spanning from 2011 to 2019, we found that the majority belonged to lineages L1 (531/732; 72.5%) and L4 (European-American; n = 174; 23.8%), with the Manila strain (L1.2.1.2.1) being the most prominent (475/531). Approximately two-thirds of isolates were found to be at least MDR-TB (483/732; 66.0%), and potential XDR-TB genotypic resistance was observed (3/732; 0.4%), highlighting an emerging problem in the country. Genotypic resistance was highly concordant with laboratory drug susceptibility testing. By finding isolates with (near-)identical genomic variation, five major clusters containing a total of 114 isolates were identified: all containing either L1 or L4 isolates with at least MDR-TB resistance and spanning multiple years of collection. Closer inspection of clusters revealed transmission in prisons, some involving isolates with XDR-TB, and mutations linked to third-line drug bedaquiline. We have also identified previously unreported mutations linked to resistance for isoniazid, rifampicin, ethambutol, and fluoroquinolones. Overall, this study provides important insights into the genetic diversity, transmission and circulating drug resistance mutations of M. tuberculosis in the Philippines, thereby informing clinical and surveillance decision-making, which is increasingly using NGS platforms.

multidisciplinary sciences
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

José Domínguez,Martin J Boeree,Emmanuelle Cambau,Dumitru Chesov,Francesca Conradie,Vivian Cox,Keertan Dheda,Andrii Dudnyk,Maha R Farhat,Sebastien Gagneux,Martin P Grobusch,Matthias I Gröschel,Lorenzo Guglielmetti,Irina Kontsevaya,Berit Lange,Frank van Leth,Christian Lienhardt,Anna M Mandalakas,Florian P Maurer,Matthias Merker,Paolo Miotto,Barbara Molina-Moya,Florence Morel,Stefan Niemann,Nicolas Veziris,Andrew Whitelaw,Charles R Horsburgh Jr,Christoph Lange,TBnet and RESIST-TB networks,Jose Domínguez,Anna Maria Mandalakas,Florian Maurer,Charles Robert Horsburgh

DOI: https://doi.org/10.1016/S1473-3099(22)00875-1

Abstract:Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the TBnet and RESIST-TB networks, about reporting standards for the clinical use of molecular drug susceptibility testing. Review and the search for evidence included hand-searching journals and searching electronic databases. The panel identified studies that linked mutations in genomic regions of M tuberculosis with treatment outcome data. Implementation of molecular testing for the prediction of drug resistance in M tuberculosis is key. Detection of mutations in clinical isolates has implications for the clinical management of patients with multidrug-resistant or rifampicin-resistant tuberculosis, especially in situations when phenotypic drug susceptibility testing is not available. A multidisciplinary team including clinicians, microbiologists, and laboratory scientists reached a consensus on key questions relevant to molecular prediction of drug susceptibility or resistance to M tuberculosis, and their implications for clinical practice. This consensus document should help clinicians in the management of patients with tuberculosis, providing guidance for the design of treatment regimens and optimising outcomes.

The problem of syphilis and gonorrhea today.

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

HSJ people. Cast adrift.

Phenylglyoxylate decarboxylase and phenylpyruvate decarboxylase fromAcinetobacter calcoaceticus

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis

Universal Lineage-Independent Markers of Multidrug Resistance in Mycobacterium tuberculosis

[Saliva and dental caries: diagnostic tests in practical dentistry].

Leveraging large-scale Mycobacterium tuberculosis whole genome sequence data to characterise drug-resistant mutations using machine learning and statistical approaches

Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan

Genetic Characterization and Population Structure of Drug-Resistant Mycobacterium tuberculosis Isolated from Brazilian Patients Using Whole-Genome Sequencing

The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis

Mutations in Dnaa and a Cryptic Interaction Site Increase Drug Resistance in Mycobacterium Tuberculosis.

Whole-genome sequencing-based genetic diversity, transmission dynamics, and drug-resistant mutations in Mycobacterium tuberculosis isolated from extrapulmonary tuberculosis patients in western Ethiopia

Molecular Mechanisms of Multiple Drug Resistance in Clinical Isolates of Mycobacterium tuberculosis

Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in Pakistan

Drug Resistance-Related Mutations in Multidrug-Resistant Mycobacterium Tuberculosis Isolates from Diverse Geographical Regions.

Overexpression of COX-2 but not indoleamine 2,3-dioxygenase-1 enhances the immunosuppressive ability of human umbilical cord-derived mesenchymal stem cells.

Whole genome sequencing identifies bacterial factors affecting transmission of multidrug-resistant tuberculosis in a high-prevalence setting

Machine Learning Predicts Accurately Mycobacterium tuberculosis Drug Resistance From Whole Genome Sequencing Data

Whole genome sequencing analysis of Mycobacterium tuberculosis reveals circulating strain types and drug-resistance mutations in the Philippines

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement